^
Association details:
| Biomarker: | FASLG overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
969 / 20 - Non-invasive detection of plasma proteins in immune checkpoint inhibitor-treated patients with advanced non-small cell lung cancer
Published date:
03/15/2023
Excerpt:
Combining the baseline expression of the two proteins identified a patient group with either a high expression of FasL or ICOSLG, or both, that had superior PFS (p=0.044) and OS....These findings suggest that the expression of FasL and ICOSLG at baseline may help identify patients who will respond to treatment with pembrolizumab.
